Key Episode Timestamps
00:00:01 Intro
00:00:19 The Sequel Twiist
00:01:05 Diabeloop's new algorithm
00:09:01 Leaving CamAPS behind?
00:09:57 Eversense approaching a spring launch
00:12:27 MiniMed Go and the InPen
00:17:40 Outro
CONTINUE TO SITE
OR WAIT null SECS
Advertisement
Advertisement
Diabetes Dialogue: Tech Updates on Twiist, MiniMed Go, and More
Published on:
Diana Isaacs, PharmD, and Natalie Bellini, DNP, review tech updates from Sequel Med Tech, Diabeloop, and Medtronic.
Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!
In this episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide an in-depth review of several notable developments in diabetes technology, focusing on innovations in insulin pump interoperability, automated insulin delivery algorithms, continuous glucose monitoring, and decision-support tools for people using multiple daily injections (MDI).
The episode begins with a major announcement from Sequel Med Tech regarding the Twiist insulin pump. Now fully commercially available after an initial limited launch, Twiist is distinguished by its interoperable design and current pairing with the Tidepool Loop algorithm. The hosts highlight Sequel’s announcement of a new partnership with Diabeloop, whose recently FDA-cleared algorithm is designed to operate as a fully closed-loop system. Unlike most existing systems, the Diabeloop algorithm does not require meal announcements, though optional meal inputs may further improve time in range. Isaacs and Bellini emphasize how this level of automation represents a significant step forward in reducing user burden, potentially rivaling or exceeding the automation seen with systems such as the Beta Bionics iLet.
The hosts explore the clinical and practical implications of offering two distinct algorithms on a single pump platform. Diabeloop’s minimal user interaction may appeal to individuals seeking simplicity or lower engagement, while Tidepool Loop’s adjustable parameters and customization options may better suit experienced users who want greater control. Bellini raises questions around how easily patients might switch between algorithms over time, drawing parallels to the flexibility clinicians currently have when changing CGM sensors. The discussion also touches on regulatory and safety considerations, with both hosts noting that algorithm switching would likely require safeguards to prevent user error.
Isaacs notes some disappointment that CamAPS, the only algorithm currently approved for use during pregnancy in the United States, is not part of Sequel’s announced partnerships. However, both hosts acknowledge the strategic rationale for selecting Diabeloop and suggest future collaborations remain possible.
The conversation then shifts to CGM integration, with confirmation that Twiist compatibility with the Eversense implantable CGM is approaching public release, following internal employee use. Anticipated availability in early spring is framed as an important milestone, particularly for patients interested in long-wear sensors. The hosts discuss benefit design considerations, emphasizing that pharmacy access to alternative CGMs may mitigate concerns about long-term commitments.
The episode concludes with discussion of Medtronic’s newly FDA-cleared MiniMed Go mobile app, designed to work with the InPen smart insulin pen. The hosts highlight improved real-time CGM integration using Medtronic’s rebranded Libre 3 Plus–based Instinct sensor, enhanced detection of missed boluses, and actionable prompts intended to support insulin dosing decisions. Bellini underscores the importance of these features for people using MDI who may not want pump therapy, positioning MiniMed Go as a meaningful advance in improving time in range and clinical support for this population.
Advertisement
Advertisement